FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508701580> ?p ?o ?g. }

• W2508701580 endingPage "69" @default.
• W2508701580 startingPage "55" @default.
• W2508701580 abstract "The European LeukemiaNet (ELN) is a network of excellence articulated in several working packages (WP) dedicated to research in haematologic malignancies. The ELN WP 4 that is dedicated to chronic myeloid leukaemia (CML) begun in 2004 to discuss the management of CML in the era of tyrosine kinase inhibitors (TKIs), in collaboration with several non-European experts. The discussion led to the elaboration of treatment recommendations that were published in 2006 (Baccarani et al. 2006). A second and a third revised versions were published in 2009 and 2013 (Baccarani et al. 2009a, 2013). These recommendations were received favourably by the scientific community, the health-care professionals, and the patients, have provided shared definitions and a common language, and in several countries have contributed to a rationale and successful management of the disease. A fourth version is in preparation. In this chapter, we do not provide a formal, comprehensive, and detailed review of the recommendations that can be better found in the original publications. Here, we discuss in more details some issues that are critical and have undergone changes since 2012, when the last version was submitted. The members of the ELN CML panel have not been involved in the preparation of this chapter. All the opinions and the suggestions that are included in this chapter reflect the opinions and the personal experience of the authors. It is not intended to modify the original ELN recommendations, but to contribute to an open discussion on some critical issues, particularly on the definition of the phases of CML, on the characteristics of old and new risk scores, and on the prognostic value of several biologic risk factors. We also discuss the response to treatment, with focus on molecular response, the first-line treatment with focus on the choice between imatinib and second-generation TKIs, and on the goals of treatment. The value of second- and third-line treatment is highlighted. The issues of treatment discontinuation for treatment-free remission (TFR) and of chronic treatment continuation in patients who cannot achieve TFR, and of BCR-ABL1+ stem cells, are discussed and reviewed." @default.
• W2508701580 created "2016-09-16" @default.
• W2508701580 creator A5009003698 @default.
• W2508701580 creator A5016041461 @default.
• W2508701580 creator A5031714115 @default.
• W2508701580 creator A5035566807 @default.
• W2508701580 creator A5044224344 @default.
• W2508701580 date "2016-01-01" @default.
• W2508701580 modified "2023-09-24" @default.
• W2508701580 title "A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia" @default.
• W2508701580 cites W1510453928 @default.
• W2508701580 cites W1584314049 @default.
• W2508701580 cites W1590650017 @default.
• W2508701580 cites W1827459324 @default.
• W2508701580 cites W1840691103 @default.
• W2508701580 cites W1901398265 @default.
• W2508701580 cites W1924236513 @default.
• W2508701580 cites W1967920366 @default.
• W2508701580 cites W1968747503 @default.
• W2508701580 cites W1973595070 @default.
• W2508701580 cites W1975541563 @default.
• W2508701580 cites W1978668514 @default.
• W2508701580 cites W1980643173 @default.
• W2508701580 cites W1984551975 @default.
• W2508701580 cites W1987239635 @default.
• W2508701580 cites W1992121712 @default.
• W2508701580 cites W1995066938 @default.
• W2508701580 cites W1996346809 @default.
• W2508701580 cites W1996661303 @default.
• W2508701580 cites W1997179318 @default.
• W2508701580 cites W1997397403 @default.
• W2508701580 cites W1997561098 @default.
• W2508701580 cites W1997730029 @default.
• W2508701580 cites W1998142988 @default.
• W2508701580 cites W1998836242 @default.
• W2508701580 cites W2008081109 @default.
• W2508701580 cites W2009579938 @default.
• W2508701580 cites W2010109350 @default.
• W2508701580 cites W2012153991 @default.
• W2508701580 cites W2014316424 @default.
• W2508701580 cites W2016809033 @default.
• W2508701580 cites W2017728128 @default.
• W2508701580 cites W2028669471 @default.
• W2508701580 cites W2028959752 @default.
• W2508701580 cites W2029303104 @default.
• W2508701580 cites W2030615871 @default.
• W2508701580 cites W2030752829 @default.
• W2508701580 cites W2031432169 @default.
• W2508701580 cites W2033661259 @default.
• W2508701580 cites W2034351069 @default.
• W2508701580 cites W2035278640 @default.
• W2508701580 cites W2036987278 @default.
• W2508701580 cites W2037837200 @default.
• W2508701580 cites W2039949576 @default.
• W2508701580 cites W2040802938 @default.
• W2508701580 cites W2049960337 @default.
• W2508701580 cites W2050904392 @default.
• W2508701580 cites W2052202516 @default.
• W2508701580 cites W2052923507 @default.
• W2508701580 cites W2057206328 @default.
• W2508701580 cites W2057796192 @default.
• W2508701580 cites W2057827171 @default.
• W2508701580 cites W2061440903 @default.
• W2508701580 cites W2061860992 @default.
• W2508701580 cites W2062166095 @default.
• W2508701580 cites W2062933371 @default.
• W2508701580 cites W2066705769 @default.
• W2508701580 cites W2068645465 @default.
• W2508701580 cites W2072703295 @default.
• W2508701580 cites W2072834954 @default.
• W2508701580 cites W2074301005 @default.
• W2508701580 cites W2074740555 @default.
• W2508701580 cites W2075706560 @default.
• W2508701580 cites W2077812841 @default.
• W2508701580 cites W2084397515 @default.
• W2508701580 cites W2086721777 @default.
• W2508701580 cites W2088660297 @default.
• W2508701580 cites W2091005492 @default.
• W2508701580 cites W2091134276 @default.
• W2508701580 cites W2092894075 @default.
• W2508701580 cites W2096285574 @default.
• W2508701580 cites W2097799776 @default.
• W2508701580 cites W2098785293 @default.
• W2508701580 cites W2099747692 @default.
• W2508701580 cites W2101513023 @default.
• W2508701580 cites W2102097468 @default.
• W2508701580 cites W2104694028 @default.
• W2508701580 cites W2107268345 @default.
• W2508701580 cites W2108470021 @default.
• W2508701580 cites W2111072132 @default.
• W2508701580 cites W2112817157 @default.
• W2508701580 cites W2113481360 @default.
• W2508701580 cites W2113835364 @default.
• W2508701580 cites W2115626434 @default.
• W2508701580 cites W2117356576 @default.
• W2508701580 cites W2117806883 @default.
• W2508701580 cites W2122224021 @default.
• W2508701580 cites W2132656575 @default.

• next